Lv11
50 积分 2023-02-24 加入
Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study
2小时前
已完结
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
3天前
已关闭
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
1个月前
已完结
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study
1个月前
已完结
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial
2个月前
已关闭
TP53 status and impact on AML prognosis within the ELN 2022 risk classification
2个月前
已完结
TP53 status and impact on AML prognosis within the ELN 2022 risk classification
2个月前
已关闭
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
2个月前
已关闭
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
2个月前
已完结
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
2个月前
已完结
皖公网安备34019202002308
